Table 3.

 Budget impact (total costs) of vaccinating different risk groups (£m) with 13 valent pneumococcal conjugate vaccine according to assumed uptakes

Risk group	Assumed uptake*
	Similar to influenza programme (base case)*	80%	Similar to annual 23 valent polysaccharide vaccination programme†
Any risk group	233	290	17.8
Splenic dysfunction	6.3	8.9	0.35
Chronic respiratory disease	34.1	41.5	2.80
Chronic heart disease	116	1411	9.60
Chronic kidney disease	71.5	83.4	6.40
Chronic liver disease	4.64	6.4	0.24
Diabetes	59.2	75.2	4.15
Immunocompromised	17.9	24.0	1.12
Infected with HIV	0.37	0.54	0.01

£1.00 ($1.6; €1.2).

*Annual influenza coverage 34.5% in 2-15 year olds, 53.6% in 16-65 year olds, and 72.4% in those aged ≥65 years.²⁷ Sum of costs of separate risk groups are higher than total costs of any risk group as people may have more than one underlying condition.

†Annual uptake 4.1% in 2-15 year olds, 1.5% in 16-65 year olds, and 7.2% in those aged ≥65 years). See appendix 7 in supplementary file.